San Diego-based Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug sector in February soon after revealing promising data from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection As well as in March the